NCT01798238View on ClinicalTrials.gov

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MP-513

form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

DRUG

Placebo

Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day

Trial Locations (2)

Unknown

Handok INC, Seoul

Handok Pharmaceuticals CO. LTD, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT01798238 - Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter